Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Papillomavirus Infections 7 Uterine Cervical Neoplasms 5 Neuroendocrine Tumors 4 Neoplasms 4 Autoimmune Diseases 3 Ovarian Neoplasms 2 Myasthenia Gravis 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Venous Thrombosis 1 Venous Thromboembolism 1 Uterine Cervical Dysplasia 1 Thyroid Diseases 1 Thrombosis 1 Squamous Intraepithelial Lesions 1 Retinal Telangiectasis 1 Renal Insufficiency 1 Recurrence 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Mesothelioma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphohistiocytosis, Hemophagocytic 1 Leukemia, Hairy Cell 1 Hemorrhage 1 Hematologic Neoplasms 1 Glioma 1 Glioblastoma 1

Interventions

Pemetrexed 23 Cisplatin 19 Nivolumab 8 Gemcitabine 7 Ipilimumab 6 Carboplatin 6 pembrolizumab 4 Bevacizumab 4 tazemetostat 3 durvalumab 3 Fluorouracil 3 Drug Therapy 3 spartalizumab 2 olaparib 2 niraparib 2 budigalimab 2 belinostat 2 anetumab ravtansine 2 amatuximab 2 Vinorelbine 2 Radiotherapy, Intensity-Modulated 2 Paclitaxel 2 PM 01183 2 Oxaliplatin 2 Imatinib Mesylate 2 Everolimus 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Cyclophosphamide 2 venetoclax 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Mesothelioma × Data Collection × Clear all

NCT05308966 2025-10-06

MESO-IMMUNE

Groupe Francais De Pneumo-Cancerologie

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡